Table 2.
Therapy | Prior | gATM | gBRCA2 | P |
---|---|---|---|---|
Abiraterone | Overall | 9/16 (56%) | 11/19 (58%) | >0.9 |
Pre-enza | 9/14 (64%) | 10/17 (59%) | ||
Post-enza | 0/2 ( 0%) | 1/2 (50%) | ||
Enzalutamide | Overall | 9/16 (56%) | 8/12 (67%) | 0.7 |
Pre-abi | 7/10 (70%) | 5/7 (71%) | ||
Post-abi | 2/6 (33%) | 3/5 (60%) | ||
Docetaxel | Overall | 9/13 (69%) | 9/16 (56%) | 0.7 |
Pre-abi/enza | 7/9 (78%) | 4/7 (57%) | ||
Post-abi/enza | 2/4 (50%) | 5/9 (56%) | ||
PARPi | Overall | 0/7 ( 0%) | 12/14 (86%) | <0.001 |
Pre-plat | 0/3 ( 0%) | 10/11 (91%) | ||
Post-plat | 0/4 ( 0%) | 2/3 (67%) |